Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind study of ANB019 in ichthyosis
2020-003476-41Phase 2Terminated
- Sponsor
- AnaptysBio, Inc.
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in ichthyosis and pustular psoriasis comparing ANB019 with Placebo (2 arms). Primary endpoint: Change from baseline in IASI total score at Week 16. Started May 2021; status: terminated.
02
Drugs
imsidolimab
03
Conditions
ichthyosispustular psoriasis
Beyond the preview
Go deeper on 2020-003476-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003476-41.